ArticleScientific reports2021
Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Molecular Structural Features and Tandem Mass Spectral Characteristics of Flavonoids From the Analysis of the LIPID MAPS Database.Chemistry & biodiversity · 2026Review
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- Enhancing Bioactive Compound Extraction from Rose Hips Using Pulsed Electric Field (PEF) Treatment: Impacts on Polyphenols, Carotenoids, Volatiles, and Fermentation Potential.Molecules (Basel, Switzerland) · 2025Article
- IL-6 Exacerbates Oxidative Damage of RPE Cells by Indirectly Destabilizing the mRNA of DNA Repair Genes.Inflammation · 2025Article
- Identification of necroptosis-related gene signatures for predicting the prognosis of ovarian cancer.Scientific reports · 2024Article
- Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported withFrontiers in pharmacology · 2024Article
- Inhibitory effect of trans-tiliroside on very low-density lipoprotein secretion in HepG2 cells and mouse liver.Journal of natural medicines · 2024Article
- Total Flavonoids inInternational journal of molecular sciences · 2023Article
- Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells.International journal of molecular sciences · 2023Article
- Phytochemical Profiling of Extracts from RareInternational journal of molecular sciences · 2023Article
- A Review on Polyphenols inNutrients · 2023Review
- Review
- Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma.World journal of gastrointestinal oncology · 2023Review
- CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment.Frontiers in immunology · 2023Review
- In vitro evaluation of immunomodulatory, anti-diabetic, and anti-cancer molecular mechanisms of Tribulus terrestris extracts.Scientific reports · 2022Article
- Review
- Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor.Cancer cell international · 2022Article
- New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells.Journal of medicinal chemistry · 2022Article
- Article
- The role of EphA7 in different tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
Corrections and comments
- Retracted
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Liver cancer is the fatal cause of cancer deaths worldwide due to its aggressiveness and lack of effective therapies. Tiliroside (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.